|
Parameter
|
M-Co
|
M-Isch
|
F-Co
|
F-Isch
|
|---|
|
BW (g)
|
205.1 ± 3.3
|
195.2 ± 5.6
|
189.8 ± 2.2
|
193.2 ± 3
|
|
SABP (mmHg)
|
136.2 ± 3.5
|
103.4 ± 5.0**
|
129.7 ± 7.4
|
114.6 ± 7.2
|
|
DABP (mmHg)
|
105.4 ± 1.9
|
81.52 ± 4.7*
|
104.22 ± 4.9
|
91.6 ± 5.3
|
|
MAP (mmHg)
|
115.2 ± 2.2
|
88.8 ± 4.7*
|
112.7 ± 5.7
|
99.2 ± 5.9
|
|
HR (bpm)
|
419.2 ± 11.2
|
408.9 ± 7.8
|
416.5 ± 12.1
|
386.3 ± 9.2
|
|
LVESV (µL)
|
53.5 ± 3.3
|
114.2 ± 21.0
|
67.7 ± 11.5
|
89.7 ± 12.6
|
|
LVEDV (µL)
|
154.6 ± 9.2
|
207.3 ± 20.7
|
195.9 ± 14.0
|
189.4 ± 17.4
|
|
LVESP (mmHg)
|
124.8 ± 3.4
|
100.1 ± 3.5*
|
128.8 ± 5.3
|
103.6 ± 6.0**
|
|
LVEDP (mmHg)
|
11.0 ± 1.1
|
11.2 ± 0.9
|
8.6 ± 0.8
|
13.6 ± 1.7*
|
|
SV (µL)
|
117.5 ± 11.3
|
111.8 ± 5.6
|
141.6 ± 5.1
|
112. ± 11.1
|
|
CO (µL/min)
|
48,694 ± 4106
|
45,785 ± 2540
|
58,968 ± 2678
|
43,175 ± 4240*
|
|
SW (mmHg*μL)
|
14,316 ± 1775
|
9455 ± 798*
|
15,111 ± 800
|
10,626 ± 1234
|
|
dP/dtmax (mmHg/s)
|
7458 ± 341
|
6612 ± 293
|
8636 ± 420
|
7531 ± 402
|
|
dP/dtmax-EDV (mmHg/(s*μL))
|
64.8 ± 3.4
|
45.7 ± 4.9
|
59.9 ± 5.9
|
54.3 ± 4.7
|
|
dP/dtmin (mmHg/s)
|
− 9322 ± 542
|
− 6677 ± 433*
|
− 11,095 ± 640
|
− 6736 ± 598***
|
- Statistical significance of post hoc test compared to same-sex control is highlighted as follows: *P < 0.05, **P < 0.01, ***P < 0.001. M-Co male control, M-Isch male ischemic, F-Co female control, F-Isch female ischemic, BW body weight, SABP systolic arterial blood pressure, DABP diastolic arterial blood pressure, HR heart rate 48 h after the first injection, LVESP left ventricular end-systolic pressure, LVEDP left ventricular end-diastolic pressure, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, SV stroke volume, CO cardiac output, SW stroke work, dP/dtmax maximal rate of rise in LV pressure, dP/dtmax-EDV maximal slope of dP/dtmax – EDV relationship, dP/dtmin maximal rate of decrease in LV pressure
